Neurocrine Biosciences
Americas · Biotech & PharmaNeurocrine initiated Phase 2 open-label study of CRENESSITY (crinecerfont) in U.S. infants and toddlers (3 months to under 4 years) with classic congenital adrenal hyperplasia, with concurrent EU trial at target enrollment. Moving toward supplemental U.S. filing to extend indication into pediatric population with no approved therapies.
curated · 2026-07-10 · context →
Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
curated · 2026-06-19 · context →
